Delivering on HopeTM

News & Events

News


Wednesday January 20, 2021

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results

Conference Call and Webcast Scheduled for Thursday, February 4 SAN DIEGO , Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq market closes on Thursday, Feb. 4, 2021 .


Friday January 08, 2021

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjusted Net Product Sales of Approximately $240 Million and $258 Million, Respectively INGREZZA® (valbenazine) Preliminary Full-Year 2020 Net Product Sales and TRx Both Grew 32% to Approximately $993 Million and


Monday January 04, 2021

Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39 th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 11, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.


Tuesday December 22, 2020

Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program

CAMBRIDGE, Mass. , Dec. 22, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences (Nasdaq: NBIX) that it has placed a clinical hold on the RESTORE-1 clinical trial of NBIb-1817


Thursday November 19, 2020

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO , Nov. 19, 2020 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences:     Matt Abernethy , Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will present at

Events